Literature DB >> 15358116

The secretable form of trimeric TRAIL, a potent inducer of apoptosis.

Mi-Hyang Kim1, Timothy R Billiar, Dai-Wu Seol.   

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a type II transmembrane cytokine molecule of the TNF family. Soluble recombinant TRAIL has been shown to induce apoptosis in a wide variety of cancer cells in vitro and to specifically limit tumor growth without damaging normal cells and tissues in vivo. These results suggest a strong potential of TRAIL as an anticancer therapy. Here we report an artificial TRAIL gene that expresses and secretes trimeric TRAIL into the culture supernatant. This novel TRAIL gene is composed of three functional elements, including a secretion signal, a trimerization domain, and an apoptosis-inducing moiety of TRAIL gene sequence. The expression vectors delivering this TRAIL gene produced secretable forms of trimeric TRAIL proteins. These TRAIL proteins showed greater apoptotic activity than the known TRAIL protein that does not contain an additional trimerization domain. Our data suggest that the gene therapy using our artificial TRAIL gene may be used as an anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358116     DOI: 10.1016/j.bbrc.2004.07.046

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Su Young Chae; Tae Hyung Kim; Kyeongsoon Park; Cheng-Hao Jin; Sohee Son; Seulki Lee; Yu Seok Youn; Kwangmeyung Kim; Dong-Gyu Jo; Ick Chan Kwon; Xiaoyuan Chen; Kang Choon Lee
Journal:  Mol Cancer Ther       Date:  2010-06-01       Impact factor: 6.261

2.  Two overlapping domains of a lyssavirus matrix protein that acts on different cell death pathways.

Authors:  Florence Larrous; Alireza Gholami; Shahul Mouhamad; Jérôme Estaquier; Hervé Bourhy
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

3.  Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: A proof of principle.

Authors:  Judit Sanchez Gil; Maxime Dubois; Virginie Neirinckx; Arnaud Lombard; Natacha Coppieters; Paolo D'Arrigo; Damla Isci; Therese Aldenhoff; Benoit Brouwers; Cédric Lassence; Bernard Rogister; Marielle Lebrun; Catherine Sadzot-Delvaux
Journal:  Mol Ther Oncolytics       Date:  2022-06-06       Impact factor: 6.311

4.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

5.  Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects.

Authors:  Cihui Yan; Xinmiao Song; Wenwen Yu; Feng Wei; Hui Li; Mengguo Lv; Xinwei Zhang; Xiubao Ren
Journal:  Tumour Biol       Date:  2016-01-05

Review 6.  Stem cells as cellular vehicles for gene therapy against glioblastoma.

Authors:  Wei Wang; Fanlong Liu; Bingyu Xiang; Charlie Xiang; Xiaozhou Mou
Journal:  Int J Clin Exp Med       Date:  2015-10-15

7.  Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.

Authors:  ZhengQiang Yuan; Krishna K Kolluri; Elizabeth K Sage; Kate H C Gowers; Sam M Janes
Journal:  Cytotherapy       Date:  2015-04-14       Impact factor: 5.414

8.  Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

Authors:  Moonsup Jeong; Yong-Sam Kwon; Soon-Hye Park; Chae-Young Kim; Sin-Soo Jeun; Kang-Won Song; Yong Ko; Paul D Robbins; Timothy R Billiar; Byong-Moon Kim; Dai-Wu Seol
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

Review 9.  Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy.

Authors:  Olivia A Diaz Arguello; Hidde J Haisma
Journal:  Cancers (Basel)       Date:  2021-03-27       Impact factor: 6.639

10.  Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.

Authors:  R Yu; L Deedigan; S M Albarenque; A Mohr; R M Zwacka
Journal:  Cell Death Dis       Date:  2013-02-21       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.